Takeda Pharmaceutical (NYSE:TAK) Downgraded by Zacks Investment Research to “Hold”

Takeda Pharmaceutical (NYSE:TAK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda’s core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan. “

Separately, ValuEngine lowered shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th.

Shares of TAK traded down $0.22 during mid-day trading on Wednesday, reaching $17.70. The company’s stock had a trading volume of 20,084 shares, compared to its average volume of 1,296,508. The firm has a market capitalization of $28.03 billion, a PE ratio of 34.71 and a beta of 0.69. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46. Takeda Pharmaceutical has a 52 week low of $15.50 and a 52 week high of $21.95. The stock’s fifty day moving average price is $17.56.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, May 14th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $3.51 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.01% and a return on equity of 11.23%. As a group, sell-side analysts expect that Takeda Pharmaceutical will post 0.39 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Coastal Investment Advisors Inc. lifted its holdings in shares of Takeda Pharmaceutical by 59.8% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock worth $32,000 after acquiring an additional 643 shares during the last quarter. Shelton Capital Management bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $46,000. Advisory Services Network LLC lifted its holdings in shares of Takeda Pharmaceutical by 101.6% in the 2nd quarter. Advisory Services Network LLC now owns 2,076 shares of the company’s stock worth $37,000 after acquiring an additional 1,046 shares during the last quarter. Hudock Capital Group LLC bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $26,000. Finally, Global Retirement Partners LLC lifted its holdings in shares of Takeda Pharmaceutical by 63.3% in the 1st quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock worth $70,000 after acquiring an additional 1,326 shares during the last quarter. Hedge funds and other institutional investors own 11.42% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Story: What is a balanced fund?

Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.